Persistence at 1 year of oral antiosteoporotic drugs: A prospective study in a comprehensive health insurance database

European Journal of Endocrinology

Volumn 166, Issue 4, 2012, Pages 735-741

  Confavreux, Cyrille B ^a   Canoui Poitrine, Florence ^a,b,c   Schott, Anne Marie ^a   Ambrosi, Véronique ^d   Tainturier, Valérie ^d   Chapurlat, Roland D ^a  

^a UNIVERSITÉ DE LYON   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d Direction Régionale du Service Médical de l'Assurance Maladie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DOSAGE SCHEDULE COMPARISON; ETHNIC GROUP; FEMALE; FRENCH LANGUAGE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; INSURANCE, MAJOR MEDICAL; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; REGISTRIES; TIME FACTORS;

EID: 84859385732     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0959     Document Type: Article

References (28)

1. Reginster JY, Rabenda V & Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006 38 S2-S6. (doi:10.1016/j.bone.2006.01.150)
2. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR & Ettinger B. Early discontinuation of treatment for osteoporosis. American Journal of Medicine 2003 115 209-216. (doi:10.1016/S0002-9343(03)00362- 0)
3. Huybrechts KF, Ishak KJ & Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006 38 922-928. (doi:10.1016/j.bone.2005.10.022)
4. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA & Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings 2006 81 1013-1022. (doi:10.4065/81.8.1013)
5. Penning-van Beest FJ, Erkens JA, Olson M & Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporosis International 2008 19 511-517. (doi:10.1007/s00198-007-0466-1)
6. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G & Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis International 2004 15 1003-1008. (doi:10.1007/s00198-004-1652-z)
7. Gallagher AM, Rietbrock S, Olson M & van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. Journal of Bone and Mineral Research 2008 23 1569-1575. (doi:10.1359/jbmr.080510)
8. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA & Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International 2008 19 811-818. (doi:10.1007/s00198-007-0506-x)
9. Gold DT, Martin BC, Frytak JR, Amonkar MM & Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Current Medical Research and Opinion 2007 23 585-594. (doi:10.1185/030079906X167615)
10. Martin-Latry K & Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiology and Drug Safety 2010 19 256-265. (doi:10.1002/pds.1912)
11. Iyer D, Buggy Y, O'Reilly K & Searle M. Strontium ranelate as a cause of acute renal failure and dress syndrome. Nephrology 2009 14 624. (doi:10.1111/j.1440-1797.2009.01125.x)
12. Jonville-Bera AP, Crickx B, Aaron L, Hartingh I & Autret-Leca E. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy 2009 64 658-659. (doi:10.1111/j.1398-9995.2009.01940.x)
13. Kramkimel N, Sibon C, Le Beller C, Saiag P & Mahe E. Bullous DRESS in a patient on strontium ranelate. Clinical and Experimental Dermatology 2009 34 e349-e350. (doi:10.1111/j.1365-2230.2009.03302.x)
14. Pernicova I, Middleton ET & Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporosis International 2008 19 1811-1812. (doi:10.1007/s00198-008-0734-8)
15. Netelenbos JC, Geusens PP, Ypma G & Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis - a large-scale, long-term retrospective study in The Netherlands. Osteoporosis International 2011 22 1537-1546. (doi:10.1007/s00198-010-1372-5)
16. Rozenberg S, Lefever A, Kroll M, Vandromme J, Paesmans M & Ham H. Prescription attitudes among gynecologists towards two particular risk factors of osteoporosis: the patient's age and her bone mineral density. Maturitas 1999 32 19-24. (doi:10.1016/S0378-5122(99)00002-X)
17. Lo JC, Pressman AR, Omar MA & Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis International 2006 17 922-928. (doi:10.1007/s00198-006-0085-2)
18. Clowes JA, Peel NF & Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 1117-1123. (doi:10.1210/jc.2003-030501)
19. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D &Watts NB. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 2007 92 1296-1304. (doi:10.1210/jc. 2006-1526)
20. Recker RR, Gallagher R & MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clinic Proceedings 2005 80 856-861. (doi:10.4065/80.7.856)
21. Cotté FE, Fardellone P, Mercier F, Gaudin AF & Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporosis International 2010 21 145-155. (doi:10.1007/s00198-009-0930-1)
22. Cooper A, Drake J & Brankin E. Treatment persistence with oncemonthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. International Journal of Clinical Practice 2006 60 896-905. (doi:10.1111/j.1742-1241.2006.01059.x)
23. Weiss TW, Henderson SC, McHorney CA & Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Current Medical Research and Opinion 2007 23 2193-2203. (doi:10.1185/030079907X226069)
24. Penning-van Beest FJ, Erkens JA, Olson M & Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Current Medical Research and Opinion 2008 24 1337-1344. (doi:10.1185/030079908X297358)
25. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M & Davis J. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007 41 122-128. (doi:10.1016/j.bone.2007.03.011)
26. Saag K, Lindsay R, Kriegman A, Beamer E & Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007 40 1238-1243. (doi:10.1016/j.bone.2007.01.016)
27. Schilcher J, Michaelsson K & Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. New England Journal of Medicine 2011 364 1728-1737. (doi:10.1056/NEJMoa1010650)
28. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS & Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2010 25 2267-2294. (doi:10.1002/jbmr.253)